Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients

Background The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis.

Published in Chemistry

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Explore the Research

SpringerLink
SpringerLink SpringerLink

Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients - BMC Oral Health

Background The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. Methods The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP + HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels. Results Stage and grade of periodontitis were stage III-IV, grade C in patients (CP + HNC post-RT), stage I-III, grade A/B in patients (CP without HNC), and absent in (healthy). Chronic periodontitis with HNC post-RT patients presented a significantly higher proportion of suPAR levels (506.7 pg/ml) compared to chronic periodontitis without HNC and healthy controls (423.08 pg/ml and 255.9 pg/ml), respectively. A significant positive correlation was found between serum suPAR levels and CAL, PPD, PI, and GBI in the periodontal disease groups. ROC results of suPAR (AUC = 0.976 for CP + HNC post-RT, AUC = 0.872 for CP without HNC). Hyposalivation appeared in patients (CP + HNC post-RT; 0.15 [0.11–0.23] ml/min, P = 0.001) and (CP without HNC; 0.30 [0.25–0.41] ml/min, P = 0.001), compared to healthy controls; 0.35 [0.28–0.54] ml/min, P = 0.001). Conclusion The study showed a significant elevation in serum suPAR levels in CP + HNC post-RT patients compared to the CP without HNC and control groups. Clinical trial registration The study was registered retrospectively; clinicaltrials.gov identifier: NCT06529588. Date of registration: July 31, 2024 https://clinicaltrials.gov/study/NCT06529588 .

Abstract
Background The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and 
endothelial homeostasis and, therefore, in the development of chronic periodontitis.
Methods The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy 
(CP+HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical 
Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were 
recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.
Results Stage and grade of periodontitis were stage III-IV, grade C in patients (CP+HNC post-RT), stage I-III, grade 
A/B in patients (CP without HNC), and absent in (healthy). Chronic periodontitis with HNC post-RT patients presented 
a significantly higher proportion of suPAR levels (506.7 pg/ml) compared to chronic periodontitis without HNC and 
healthy controls (423.08 pg/ml and 255.9 pg/ml), respectively. A significant positive correlation was found between 
serum suPAR levels and CAL, PPD, PI, and GBI in the periodontal disease groups. ROC results of suPAR (AUC=0.976 
for CP+HNC post-RT, AUC=0.872 for CP without HNC). Hyposalivation appeared in patients (CP+HNC post-RT; 0.15 
[0.11–0.23] ml/min, P=0.001) and (CP without HNC; 0.30 [0.25–0.41] ml/min, P=0.001), compared to healthy controls; 
0.35 [0.28–0.54] ml/min, P=0.001).
Conclusion The study showed a significant elevation in serum suPAR levels in CP+HNC post-RT patients compared 
to the CP without HNC and control groups.
Clinical trial registration The study was registered retrospectively; clinicaltrials.gov identifier: NCT06529588. Date of 
registration: July 31, 2024 https://clinicaltrials.gov/study/NCT06529588.
Keywords Chronic periodontitis, Head and neck cancer, Radiotherapy, suPAR

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Biological Chemistry
Physical Sciences > Chemistry > Biological Chemistry
  • BMC Oral Health BMC Oral Health

    This is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of disorders of the mouth, teeth and gums, as well as related molecular genetics, pathophysiology, and epidemiology.

Related Collections

With collections, you can get published faster and increase your visibility.

Systemic disease and oral health

BMC Oral Health is pleased to announce our upcoming Collection on Systemic disease and oral health. The interrelationship between systemic diseases and oral health has garnered increasing attention in recent years. Research has shown that conditions such as diabetes, cardiovascular disease, and respiratory illnesses can significantly impact oral health, while poor oral health can exacerbate systemic diseases. This Collection aims to explore the multifaceted connections between systemic health and oral conditions, emphasizing the importance of an integrated approach to healthcare that recognizes the bidirectional nature of these relationships. We invite researchers to contribute studies that investigate the mechanisms underlying these connections and their implications for clinical practice.

Continued exploration in this field could yield significant advancements in personalized healthcare approaches, leading to more effective prevention and treatment strategies. Building on the contributions from our previous Collection, Oral and systemic health, we aim to enhance our understanding of how systemic diseases influence oral health. We may also uncover new strategies for early diagnosis and interventions tailored to individual patient profiles.

We invite submissions on a range of topics that include but are not limited to:

- The impact of diabetes on oral health

- Cardiovascular disease and periodontal disease connections

- Respiratory disease and oral health implications

- Oral health in patients with rheumatoid arthritis

- The role of oral health in cancer treatment outcomes

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Mar 11, 2026

In vitro models for biocompatibility testing

BMC Oral Health is pleased to announce our upcoming Collection on In vitro models for biocompatibility testing. Evaluating biocompatibility is a critical aspect of developing dental materials, as it ensures that these materials do not elicit adverse biological responses when used in clinical applications. In vitro models, including cell culture and tissue engineering approaches, have emerged as essential tools for assessing the compatibility of dental materials with human tissues, particularly in restorative dentistry. These models allow researchers to simulate the oral environment, providing insights into the interactions between dental materials and biological systems, which is crucial for the safe and effective use of these materials in dental practice.

As research grows, we can anticipate the development of more sophisticated in vitro models that closely mimic the complex architecture and functionality of oral tissues. Future advances may include the use of organ-on-a-chip technologies and bioengineered tissues, which could provide even more reliable data on the biocompatibility of dental materials. These developments will not only enhance our understanding of material interactions but also facilitate the design of safer and more effective dental products.

We invite submissions on a range of topics that include but are not limited to:

• Biocompatibility of dental materials

• 3D models in dental research

• Cell culture techniques for toxicity testing

• Tissue engineering applications in restorative dentistry

• Assessing dental pulp responses to materials

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

Publishing Model: Open Access

Deadline: Oct 03, 2025